Zobrazeno 1 - 10
of 29
pro vyhledávání: '"J V Teichmann"'
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 115:743-748
Autor:
J. V. Teichmann, E. Thiel
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 115:703-707
Autor:
E. Odenwald, C Sperling, J V Teichmann, W.-D. Ludwig, H. Riehm, A. Reiter, J. Ritter, B. Komischke, S Sauter
Publikováno v:
Klinische Pädiatrie. 202:243-252
In the therapy studies ALL-BFM 83 and 86, immunophenotyping of ALL by monoclonal antibodies was performed in a total of 1162 protocol patients (ALL-BFM 83 n = 578; ALL-BFM 86 n = 584). Both studies yielded similar results with respect to the incidenc
Autor:
J. V. Teichmann, E. Odenwald, A. Nehmer, Eckhard Thiel, W.-D. Ludwig, Michael Notter, Hansjörg Riehm, J. Harbott, C. Sperling, B. Komischke, H. Seibt-Jung, C. R. Bartram
Publikováno v:
Recent Advances in Cell Biology of Acute Leukemia ISBN: 9783642848971
Due to the increasing availability of monoclonal antibodies (MAbs) recognizing lymphoid-, myeloid-, and progenitor-cell-associated antigens, immunophenotyping has greatly influenced studies on the biologic features of normal and leukemic hematopoieti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e87e763739df5078e3609226a47705f
https://doi.org/10.1007/978-3-642-84895-7_24
https://doi.org/10.1007/978-3-642-84895-7_24
Autor:
W D, Ludwig, J, Harbott, C R, Bartram, B, Komischke, C, Sperling, J V, Teichmann, H, Seibt-Jung, M, Notter, E, Odenwald, A, Nehmer
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 131
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 131
Publikováno v:
Recent Advances in Cell Biology of Acute Leukemia ISBN: 9783642848971
Interleukin-2- (IL-2-)activated cytotoxic effector cells, known as lymphokine- activated killer (LAK) cells, lyse a wide variety of fresh solid tumor cells (Grimm et al. 1982; Itoh et al. 1986) as well as fresh noncultured leukemia cells (Oshimi et a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::243f52b50f826d915fee2384cb1cf8e1
https://doi.org/10.1007/978-3-642-84895-7_20
https://doi.org/10.1007/978-3-642-84895-7_20
Publikováno v:
Natural immunity. 11(3)
The present study investigated the susceptibility of human leukemia cells to allogeneic lymphocytes with lymphokine-activated killer (LAK) activity from normal donors and autologous LAK activity from patients in complete remission. LAK activity was g
Publikováno v:
Cytokines in Hemopoiesis, Oncology, and AIDS II ISBN: 9783540552420
Interleukin-2 (IL-2) is known to activate cytotoxic effector cells which are able to lyse fresh solid tumor cells [1, 2] as well as fresh noncultured leukemia cells [3–6]. These activated cytotoxic effector cells, known as lymphokine-activated kill
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5c2bf5489e44f106c6cf4aa99c3116c
https://doi.org/10.1007/978-3-642-48715-6_44
https://doi.org/10.1007/978-3-642-48715-6_44
Publikováno v:
Leukemia research. 16(3)
Adoptive immunotherapy with interleukin 2-induced lymphokine-activated killer (LAK) cells or tumor-infiltrating lymphocytes (TIL) and the induction of anti-tumor responses by IL-2 alone having proven to be promising approaches in cancer therapy. The